Cargando…

A phase Ib study of adavosertib, a selective Wee1 inhibitor, in patients with locally advanced or metastatic solid tumors

Adavosertib selectively inhibits Wee1, which regulates intra-S and G2/M cell-cycle checkpoints. This study investigated dosing schedules for adavosertib monotherapy, determining the maximum tolerated dose (MTD) and recommended Phase II dose (RP2D) in patients with advanced solid tumors. Patients rec...

Descripción completa

Detalles Bibliográficos
Autores principales:	Falchook, Gerald S, Sachdev, Jasgit, Imedio, Esteban Rodrigo, Kumar, Sanjeev, Mugundu, Ganesh M, Jenkins, Suzanne, Chmielecki, Juliann, Jones, Suzanne, Spigel, David R, Johnson, Melissa
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer US 2023
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10289903/ https://www.ncbi.nlm.nih.gov/pubmed/37171722 http://dx.doi.org/10.1007/s10637-023-01371-6

Ejemplares similares

A Phase Ib Study Assessing the Safety, Tolerability, and Efficacy of the First-in-Class Wee1 Inhibitor Adavosertib (AZD1775) as Monotherapy in Patients with Advanced Solid Tumors
por: Bauer, Todd M., et al.
Publicado: (2023)

Effect of food on the pharmacokinetics of the WEE1 inhibitor adavosertib (AZD1775) in patients with advanced solid tumors
por: Någård, Mats, et al.
Publicado: (2020)

Safety, Pharmacokinetics, and Clinical Activity of Adavosertib in Combination with Chemotherapy in Asian Patients with Advanced Solid Tumors: Phase Ib Study
por: Kato, Hidenori, et al.
Publicado: (2020)

Targeted inhibition of the methyltransferase SETD8 synergizes with the Wee1 inhibitor adavosertib in restraining glioblastoma growth
por: Della Monica, Rosa, et al.
Publicado: (2023)

Adavosertib (AZD1775) does not prolong the QTc interval in patients with advanced solid tumors: a phase I open-label study
por: Någård, Mats, et al.
Publicado: (2023)

Effects of Wee1 inhibitor adavosertib on patient-derived high-grade serous ovarian cancer cells are multiple and independent of homologous recombination status
por: Roering, Pia, et al.
Publicado: (2022)

Inhibition of WEE1 Is Effective in TP53- and RAS-Mutant Metastatic Colorectal Cancer: A Randomized Trial (FOCUS4-C) Comparing Adavosertib (AZD1775) With Active Monitoring
por: Seligmann, Jenny F., et al.
Publicado: (2021)

Phase I study to assess the effect of adavosertib (AZD1775) on the pharmacokinetics of substrates of CYP1A2, CYP2C19, and CYP3A in patients with advanced solid tumors
por: Någård, Mats, et al.
Publicado: (2023)

Wee1 kinase inhibitor adavosertib with radiation in newly diagnosed diffuse intrinsic pontine glioma: A Children’s Oncology Group phase I consortium study
por: Mueller, Sabine, et al.
Publicado: (2022)

Efficacy and Biomarker Analysis of Adavosertib in Differentiated Thyroid Cancer
por: Lu, Yu-Ling, et al.
Publicado: (2021)

Synergistic interactions of cytarabine-adavosertib in leukemic cell lines proliferation and metabolomic endpoints
por: Rodríguez-Vázquez, Gabriel O., et al.
Publicado: (2023)

Adavosertib Enhances Antitumor Activity of Trastuzumab Deruxtecan in HER2-Expressing Cancers
por: DiPeri, Timothy P., et al.
Publicado: (2023)

Ricolinostat enhances adavosertib-induced mitotic catastrophe in TP53-mutated head and neck squamous cell carcinoma cells
por: Miyake, Keitaro, et al.
Publicado: (2022)

A Phase Ib Dose-Escalation Study of LCL161 Plus Oral Topotecan for Patients With Relapsed/Refractory Small Cell Lung Cancer and Select Gynecologic Malignancies
por: Johnson, Melissa L, et al.
Publicado: (2023)

Air raids and the 'Wee' Hospital.
por: Logan, C. J. H.
Publicado: (2003)

Phase Ib study of eprenetapopt (APR-246) in combination with pembrolizumab in patients with advanced or metastatic solid tumors
por: Park, H., et al.
Publicado: (2022)

Bromodomain and Extra-Terminal (BET) Domain Protein Inhibitors for Solid Tumor Cancers
por: Nguyen, Martin V., et al.
Publicado: (2020)

A Wee Lesson in Science Communication
por: King, Emma
Publicado: (2004)

Pedicures, wees alert op ‘coronatenen’
por: van Putten, Margreet
Publicado: (2020)

WEE1 Inhibitor: Clinical Development
por: Kong, Anthony, et al.
Publicado: (2021)

Cdc25 and Wee1: analogous opposites?
por: Perry, Jennifer A, et al.
Publicado: (2007)

WEE1 inhibition sensitizes osteosarcoma to radiotherapy
por: PosthumaDeBoer, Jantine, et al.
Publicado: (2011)

Phase 1 study of MRX34, a liposomal miR-34a mimic, in patients with advanced solid tumours
por: Hong, David S., et al.
Publicado: (2020)

Phase 1/2 study of epacadostat in combination with durvalumab in patients with metastatic solid tumors
por: Naing, Aung, et al.
Publicado: (2022)

A Phase Ib Study of Axitinib in Combination with Crizotinib in Patients with Metastatic Renal Cell Cancer or Other Advanced Solid Tumors
por: Michaelson, M. Dror, et al.
Publicado: (2019)

A Wee1 checkpoint inhibits anaphase onset
por: Lianga, Noel, et al.
Publicado: (2013)

Phase Ib Study of Atezolizumab Plus Interferon-α with or without Bevacizumab in Patients with Metastatic Renal Cell Carcinoma and Other Solid Tumors
por: Blank, Christian U., et al.
Publicado: (2021)

Suvemcitug as second-line treatment of advanced or metastatic solid tumors and with FOLFIRI for pretreated metastatic colorectal cancer: phase Ia/Ib open label, dose-escalation trials
por: Mao, C., et al.
Publicado: (2023)

Phase I study of liposomal irinotecan in patients with metastatic breast cancer: findings from the expansion phase
por: Sachdev, Jasgit C., et al.
Publicado: (2020)

Induction of BIM Is Essential for Apoptosis Triggered by EGFR Kinase Inhibitors in Mutant EGFR-Dependent Lung Adenocarcinomas
por: Gong, Yixuan, et al.
Publicado: (2007)

Safety and pharmacokinetics of veliparib extended‐release in patients with advanced solid tumors: a phase I study
por: Werner, Theresa L., et al.
Publicado: (2018)

Selinexor in combination with topotecan in patients with advanced or metastatic solid tumors: Results of an open-label, single-center, multi‐arm phase Ib study
por: Thein, Kyaw Zin, et al.
Publicado: (2021)

Spatiotemporal regulations of Wee1 at the G2/M transition
por: Masuda, Hirohisa, et al.
Publicado: (2011)

Regulation of wee1(+) expression during meiosis in fission yeast
por: Murakami-Tonami, Yuko, et al.
Publicado: (2014)

CENPE promotes glioblastomas proliferation by directly binding to WEE1
por: Ma, Chuanling, et al.
Publicado: (2020)

Association between immune-mediated adverse events and efficacy in metastatic non-small-cell lung cancer patients treated with durvalumab and tremelimumab
por: Dey, Agnish, et al.
Publicado: (2022)

A phase Ib combination study of RO4929097, a gamma-secretase inhibitor, and temsirolimus in patients with advanced solid tumors
por: Diaz-Padilla, Ivan, et al.
Publicado: (2013)

Value of adjuvant chemotherapy in patients with resected stage IB solid predominant and solid non‐predominant lung adenocarcinoma
por: Cao, Shuhui, et al.
Publicado: (2018)

Development of a multiscale mechanistic modeling framework integrating differential cellular kinetics of CAR T‐cell subsets and immunophenotypes in cancer patients
por: Salem, Ahmed M., et al.
Publicado: (2023)

Positioning of second‐line treatment for advanced gastric and gastroesophageal junction adenocarcinoma
por: Pericay, Carles, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_5u9vfltmms3kfcardr8h3are40